MedPath

TA-65 and Aging Associated Microvascular Dysfunction

Not Applicable
Not yet recruiting
Conditions
Aging
Telomere Shortening
Vascular Diseases
Registration Number
NCT05598359
Lead Sponsor
Medical College of Wisconsin
Brief Summary

The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.

Detailed Description

The purpose of this clinical trial is to examine whether activation of autophagy with TA-65 which activates telomerase, improves microvascular function and blood pressure in an older population

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
180
Inclusion Criteria
  • Healthy Adults 18 - 35 and 65+ years of age
  • Subjects with clinical diagnosis of CAD

Exclusion criteria will include:

  • 36-64 years of age without clinical diagnosis of CAD
  • Self-reported habitual vigorous exercise (>20 min, 3 times per week, 1 yr)
  • Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)
  • Heart Failure
  • Renal Impairment
  • >3 Pre-existing Cardiovascular Risk Factors (healthy groups only)
  • Type 1 or type 2 diabetes
  • Uncontrolled hypertension
  • Current tobacco use or within last 6 months
  • BMI > 35
  • Hyperlipidemia
  • Hypercholesterolemia
  • Use of anti-coagulant drugs
  • Use of anti-platelet drugs
  • Erectile dysfunction medication in the past 6 months
  • Use of topical/non-topical steroids in last 6 months
  • Hormone replacement therapy (Post-Menopause or Gender Reassignment)
  • History of retinopathy
  • Documented neuromuscular disorders
  • Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
  • Pregnancy (young female subjects)
  • Allergy to lidocaine
  • Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months
  • Active COVID-19 or within the past 3 months
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis28 days

Cutaneous microvascular function measured via laser Doppler flowmetry coupled with intradermal microdialysis of non-specific nitric oxide synthase inhibitor, L-NAME

Secondary Outcome Measures
NameTimeMethod
Systemic Blood Pressure28 days

Brachial systolic, and diastolic blood pressure will be measured via standard brachial blood pressure cuff

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.